Video supervised rapid testing for the detection of SARS-CoV-2 antigens for Fit-to-Fly testing. Booking link for easy customer scheduling with appointment availability 7-days a week. Digital Validation Report issued immediately following appointment.
Is a single-stranded positive-sense RNA virus that causes COVID-19 with symptoms including coughing, loss of taste or small, fever, headaches and can lead to respiratory distress 1,2. SARS-CoV-2 viral particles use spike protein to bind to its human cell surface receptor, ACE2, and enter the cell with subsequent fusion with cell membrane 3. The virus particle is uncoated, releasing the genomic RNA into the host cell. The viral genomic RNA uses the host’s ‘machinery’, to produce more viral particles which are secreted from the infected cell 4. As of the beginning of April 2022, over 21,400,000 people have tested positive for SARS-CoV-2 and over 187,000 have died in the UK alone with the Omicron BA.2 variant the most dominant in the UK accounting for over 93% of cases in England5-7.
The Lateral Flow Device provides rapid SARS-CoV-2 detection utilising specific anti-SARS-CoV-2 specific to detect the nucleocapsid antigens. The samples are obtained through anterior nasal swabs which are combined with the extraction solution. Results are visually read at 15-30 minutes. A red line would appear at the Control (C) line if the test had worked. A red line at position T indicates SARS-CoV-2 presence.
SARS-CoV-2 (Nucleocapsid antigens)
Limit of Detection
Clinical Performance characteristics
Relative Sensitivity 97.1% Relative Specificity 99.5%
Turn Around Time
Receive results within 15-30 minutes of appointment
Time for Validation Report
15-30 mins after online appointment (9am-9pm, 7 days a week)
1 Test Cassette
1 Extraction Buffer Tube
1 Disposable Swab
1 Waste Bag
Store kits between 2 – 30°C
Use kits before expiration date printed on sealed test kit.
The test must remain in the sealed pouch until use.
1. Stowe J, Tessier E, Zhao H, Guy R, Muller-Pebody B, Zambon M, et al. Interactions between SARS-CoV-2 and influenza, and the impact of coinfection on disease severity: a test-negative design. Int J Epidemiol. 2021 May 3;50(4):1124–33.
2. World Health Organization. Coronavirus [Internet]. [cited 2022 Apr 13]. Available from: https://www.who.int/health-topics/coronavirus
3. Jackson CB, Farzan M, Chen B, Choe H. Mechanisms of SARS-CoV-2 entry into cells. Nat Rev Mol Cell Biol. 2022 Jan;23(1):3–20.
4. V’kovski P, Kratzel A, Steiner S, Stalder H, Thiel V. Coronavirus biology and replication: implications for SARS-CoV-2. Nat Rev Microbiol. 2021 Mar;19(3):155–70.
5. UK Health Security Agency. Cases in the UK | Coronavirus in the UK [Internet]. [cited 2022 Apr 14]. Available from: https://coronavirus.data.gov.uk/details/cases
6. UK Health Security Agency. Deaths in the UK | Coronavirus in the UK [Internet]. [cited 2022 Apr 14]. Available from: https://coronavirus.data.gov.uk/details/deaths
7. UK Health Security Agency. COVID-19 variants identified in the UK [Internet]. GOV.UK. [cited 2022 Apr 14]. Available from: https://www.gov.uk/government/news/covid-19-variants-identified-in-the-uk